Teva Settles Price Fixing Charges With U.S. DOJ; Teva Will Pay A $225M Fine Over 5-Years With $22.5M Due Each Year From 2024 Through 2027 And $135M Due In 2028
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. has settled price fixing charges with the U.S. Department of Justice (DOJ). The company will pay a $225 million fine over five years, with $22.5 million due each year from 2024 through 2027 and $135 million due in 2028.
August 21, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Teva's settlement with the DOJ over price fixing charges will result in a $225 million fine spread over five years. This could impact the company's financials and potentially its stock price.
The settlement will result in a significant financial burden for Teva over the next five years. This could potentially affect the company's profitability and, in turn, its stock price. The news is highly relevant as it directly involves Teva and is important for investors due to the potential financial impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100